Advertisement
Advertisement

VIR

VIR logo

Vir Biotechnology, Inc. Common Stock

7.44
USD
Sponsored
-0.34
-4.36%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

7.21

-0.24
-3.17%

VIR Earnings Reports

Positive Surprise Ratio

VIR beat 9 of 25 last estimates.

36%

Next Report

Date of Next Report
Feb 19, 2026
Estimate for Q4 25 (Revenue/ EPS)
$23.41M
/
-$0.49
Implied change from Q3 25 (Revenue/ EPS)
+9656.18%
/
-58.12%
Implied change from Q4 24 (Revenue/ EPS)
+89.23%
/
-35.53%

Vir Biotechnology, Inc. Common Stock earnings per share and revenue

On Nov 05, 2025, VIR reported earnings of -1.17 USD per share (EPS) for Q3 25, missing the estimate of -0.86 USD, resulting in a -35.70% surprise. Revenue reached 240.00 thousand, compared to an expected 2.00 million, with a -88.02% difference. The market reacted with a -5.19% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 23.41 million USD, implying an decrease of -58.12% EPS, and increase of 9656.18% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Vir Biotechnology, Inc. Common Stock reported EPS of -$1.17, missing estimates by -35.7%, and revenue of $240.00K, -88.02% below expectations.
The stock price moved down -5.19%, changed from $5.40 before the earnings release to $5.12 the day after.
The next earning report is scheduled for Feb 19, 2026.
Based on 10 analysts, Vir Biotechnology, Inc. Common Stock is expected to report EPS of -$0.49 and revenue of $23.41M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement